{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:48Z","timestamp":1792636788988,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Seagen Inc"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221745"],"award-info":[{"award-number":["P50CA221745"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer (la\/mUC) previously treated with a platinum-based chemotherapy and a programmed death receptor-1\/programmed death-ligand 1 (PD-1\/L1) inhibitor, or patients with la\/mUC who are ineligible for cisplatin-based chemotherapy and have previously received one or more prior lines of therapy. Enfortumab vedotin is the only drug to have demonstrated survival benefit versus chemotherapy in a randomized controlled trial in patients with la\/mUC previously treated with platinum-based chemotherapy and a PD-1\/L1 inhibitor. The development of dermatologic events following the administration of enfortumab vedotin is anticipated given the expression of Nectin-4 in epidermal keratinocytes and skin appendages (eg, sweat glands and hair follicles). There is the potential for rare but severe and possibly fatal cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis, as described in the boxed warning of the US prescribing information for enfortumab vedotin. This manuscript describes the presumed pathophysiology and manifestations of dermatologic reactions related to enfortumab vedotin, and presents recommendations for prevention and treatment, to provide oncologists and other healthcare providers with an awareness of these potential adverse events to best anticipate and manage them.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac001","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T20:12:21Z","timestamp":1643055141000},"page":"e223-e232","source":"Crossref","is-referenced-by-count":162,"title":["Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-3710","authenticated-orcid":false,"given":"Mario E","family":"Lacouture","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Weill Cornell Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-784X","authenticated-orcid":false,"given":"Anisha B","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-4249","authenticated-orcid":false,"given":"Jonathan E","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Weill Cornell Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-0049","authenticated-orcid":false,"given":"Peter H","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"2022031109003476600_CIT0001","author":"National Cancer Institute.","year":"2021"},{"key":"2022031109003476600_CIT0002","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res."},{"key":"2022031109003476600_CIT0003","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.3390\/ijms21238993","article-title":"Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: a comprehensive review.","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"2","key":"2022031109003476600_CIT0004","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines.","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist."},{"issue":"30","key":"2022031109003476600_CIT0005","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events.","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol."},{"issue":"36","key":"2022031109003476600_CIT0006","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022031109003476600_CIT0007","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models.","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"2022031109003476600_CIT0008","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1038\/oncsis.2014.32","article-title":"Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.","volume":"3(9)","author":"Lattanzio","year":"2014","journal-title":"Oncogenesis."},{"issue":"2","key":"2022031109003476600_CIT0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajhg.2010.07.003","article-title":"Mutations in PVRL4, encoding cell adhesion molecule Nectin-4, cause ectodermal dysplasia-syndactyly syndrome.","volume":"87","author":"Brancati","year":"2010","journal-title":"Am J Hum Genet."},{"issue":"16","key":"2022031109003476600_CIT0010","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.3390\/ijms21165891","article-title":"Nectin4 expression in extramammary Paget\u2019s disease: Implication of a new therapeutic target.","volume":"21","author":"Murata","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"5","key":"2022031109003476600_CIT0011","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ceb.2007.09.007","article-title":"The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors.","volume":"19","author":"Sakisaka","year":"2007","journal-title":"Curr Opin Cell Biol."},{"issue":"8","key":"2022031109003476600_CIT0012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation.","volume":"9","author":"Takai","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"29","key":"2022031109003476600_CIT0013","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy.","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol."},{"key":"2022031109003476600_CIT0014","doi-asserted-by":"crossref","first-page":"e00358","DOI":"10.7554\/eLife.00358","article-title":"A role for PVRL4-driven cell-cell interactions in tumorigenesis.","volume":"2","author":"Pavlova","year":"2013","journal-title":"Elife."},{"issue":"16","key":"2022031109003476600_CIT0015","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer.","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"2022031109003476600_CIT0016","first-page":"8789","article-title":"High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer.","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett."},{"issue":"1","key":"2022031109003476600_CIT0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","article-title":"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer.","volume":"34","author":"Nishiwada","year":"2015","journal-title":"J Exp Clin Cancer Res."},{"issue":"5","key":"2022031109003476600_CIT0018","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.","volume":"134","author":"Derycke","year":"2010","journal-title":"Am J Clin Pathol."},{"key":"2022031109003476600_CIT0019","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.","volume":"28","author":"M-Rabet","year":"2017","journal-title":"Ann Oncol."},{"issue":"9","key":"2022031109003476600_CIT0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.prp.2017.07.019","article-title":"Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer.","volume":"213","author":"Rajc","year":"2017","journal-title":"Pathol Res Pract."},{"issue":"1","key":"2022031109003476600_CIT0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","article-title":"A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth.","volume":"375","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"2022031109003476600_CIT0022","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5603\/FHC.2011.0005","article-title":"The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma.","volume":"49","author":"Athanassiadou","year":"2011","journal-title":"Folia Histochem Cytobiol."},{"issue":"7","key":"2022031109003476600_CIT0023","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy.","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol."},{"key":"2022031109003476600_CIT0024","author":"Seagen and Astellas Pharma US Inc.","year":"2021"},{"issue":"12","key":"2022031109003476600_CIT0025","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med."},{"key":"2022031109003476600_CIT0026","first-page":"Abstract 5581","article-title":"Enfortumab vedotin, an anti-nectin-4 adc demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; April 27-28, 2020, and June 22-24, 2020. Philadelphia (PA): AACR.","volume-title":"Cancer Res.","author":"Liu","year":"2020"},{"issue":"2","key":"2022031109003476600_CIT0027","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1188\/21.CJON.E1-E9","article-title":"Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma.","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs."},{"issue":"5","key":"2022031109003476600_CIT0028","first-page":"e8102","article-title":"Flexural exanthema from enfortumab vedotin.","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus."},{"key":"2022031109003476600_CIT0029","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J."},{"issue":"6","key":"2022031109003476600_CIT0030","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"2022031109003476600_CIT0031","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdv.13475","article-title":"Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy.","volume":"30","author":"Prieto-Torres","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"10106","key":"2022031109003476600_CIT0032","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs.","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet."},{"issue":"Suppl 1","key":"2022031109003476600_CIT0033","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails.","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"2022031109003476600_CIT0034","volume-title":"Symmetrical Drug-related Intertriginous and Flexural Exanthema.","author":"Harbaoui","year":"2022"},{"issue":"4","key":"2022031109003476600_CIT0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/ACI.0b013e3283489d5f","article-title":"Symmetrical drug-related intertriginous and flexural exanthema.","volume":"11","author":"Tan","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol."},{"issue":"8","key":"2022031109003476600_CIT0036","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances.","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Saf."},{"issue":"6","key":"2022031109003476600_CIT0037","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial.","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022031109003476600_CIT0038","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"2","key":"2022031109003476600_CIT0039","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology.","volume":"25","author":"Rosen","year":"2014","journal-title":"Anticancer Drugs."},{"issue":"3","key":"2022031109003476600_CIT0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","article-title":"Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review.","volume":"81","author":"Weinkle","year":"2019","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"2022031109003476600_CIT0041","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamadermatol.2020.1795","article-title":"Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center.","volume":"156","author":"Yu","year":"2020","journal-title":"JAMA Dermatol."},{"issue":"8","key":"2022031109003476600_CIT0042","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022031109003476600_CIT0043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000497232","article-title":"Prophylaxis and management of skin toxicities.","volume":"14","author":"Salzmann","year":"2019","journal-title":"Breast Care (Basel)."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/3\/e223\/42828458\/oyac001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/3\/e223\/42828458\/oyac001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T09:01:52Z","timestamp":1646989312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/3\/e223\/6537593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,26]]},"published-print":{"date-parts":[[2022,3,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac001","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2022,2,26]]}}}